Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. Moderna faces significant commercial challenges, particularly in ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

The Nova 301 trial will see a vaccine developed by pharmaceutical firm Moderna and 2,500 volunteers in the UK taking part. Like Moderna's vaccine used in the COVID-19 vaccination campaign ...

The plot has thickened in the Justin Trudeau-Heinz ketchup controversy, as consumers with bottles that say "Product of USA" question how Canadian the popular condiment really is. Kraft Heinz took ...

As part of a novel initiative to combat plastic waste, UK households will be rewarded for returning empty bottles to their local supermarkets. This deposit return scheme, already implemented in ...

After years of lugging around wide-mouth insulated bottles (and not-so-gracefully chugging them at the gym), the brand’s proprietary hidden straw truly spoke to me. If you’ve ever tried ...